AU2014374259A1 - Novel compositions - Google Patents

Novel compositions

Info

Publication number
AU2014374259A1
AU2014374259A1 AU2014374259A AU2014374259A AU2014374259A1 AU 2014374259 A1 AU2014374259 A1 AU 2014374259A1 AU 2014374259 A AU2014374259 A AU 2014374259A AU 2014374259 A AU2014374259 A AU 2014374259A AU 2014374259 A1 AU2014374259 A1 AU 2014374259A1
Authority
AU
Australia
Prior art keywords
composition
naphthalen
azabicyclo
hexane
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014374259A
Other languages
English (en)
Inventor
Matthew Greene
Anthony Mckinney
Brian Mcmillan
Walter Piskorski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurovance Inc
Original Assignee
Neurovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovance Inc filed Critical Neurovance Inc
Publication of AU2014374259A1 publication Critical patent/AU2014374259A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014374259A 2013-12-09 2014-12-09 Novel compositions Abandoned AU2014374259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913886P 2013-12-09 2013-12-09
US61/913,886 2013-12-09
PCT/US2014/069416 WO2015102826A1 (en) 2013-12-09 2014-12-09 Novel compositions

Publications (1)

Publication Number Publication Date
AU2014374259A1 true AU2014374259A1 (en) 2016-07-21

Family

ID=53371779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014374259A Abandoned AU2014374259A1 (en) 2013-12-09 2014-12-09 Novel compositions

Country Status (8)

Country Link
US (3) US20160303077A1 (cg-RX-API-DMAC7.html)
EP (1) EP3080080A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017502948A (cg-RX-API-DMAC7.html)
KR (1) KR20160101012A (cg-RX-API-DMAC7.html)
CN (1) CN106029637A (cg-RX-API-DMAC7.html)
AU (1) AU2014374259A1 (cg-RX-API-DMAC7.html)
CA (1) CA2936108A1 (cg-RX-API-DMAC7.html)
WO (2) WO2015089111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016155A2 (en) 2005-07-27 2007-02-08 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160303077A1 (en) * 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
NZ776973A (en) 2015-06-17 2022-11-25 Otsuka America Pharmaceutical Inc Crystalline compounds
WO2018119291A1 (en) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Synthetic methods
JP7399850B2 (ja) 2018-04-26 2023-12-18 株式会社エーピーアイ コーポレーション 芳香族ニトリル化合物の製造方法
EP3950664A4 (en) 2019-10-29 2022-05-11 API Corporation HIGH PURITY 2-NAPHTHYLACETONITRILE AND PROCESS FOR PRODUCTION THEREOF
WO2022181625A1 (en) 2021-02-23 2022-09-01 Otsuka Pharmaceutical Co., Ltd. Centanafadine pharmaceutical formulations, and methods of making and using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640120A1 (en) 2005-03-08 2006-09-14 Dov Pharmaceutical, Inc. Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo(3.1.0) hexanes
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
WO2007016155A2 (en) * 2005-07-27 2007-02-08 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
US20080058535A1 (en) 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
JP2013544850A (ja) 2010-12-03 2013-12-19 ユーシミクス バイオサイエンス，インク． モノアミン神経伝達物質によって影響を受ける病態の処置における（＋）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの調製および使用
WO2012118563A2 (en) * 2011-03-03 2012-09-07 Vanderbilt University 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
PL2819516T3 (pl) * 2011-07-30 2020-08-10 Otsuka America Pharmaceutical, Inc. Zastosowanie (1 R,5S-(+)-1-(naftalen-2-ylo)-3-azabicyklo{3.1.0}heksanu w leczeniu stanów wywołanych przez neuroprzekaźniki monoaminowe
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20160303077A1 (en) 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
NZ776973A (en) 2015-06-17 2022-11-25 Otsuka America Pharmaceutical Inc Crystalline compounds

Also Published As

Publication number Publication date
KR20160101012A (ko) 2016-08-24
CA2936108A1 (en) 2015-07-09
WO2015089111A1 (en) 2015-06-18
WO2015102826A1 (en) 2015-07-09
US20160303076A1 (en) 2016-10-20
JP2017502948A (ja) 2017-01-26
US20160303077A1 (en) 2016-10-20
US9839627B2 (en) 2017-12-12
EP3080080A4 (en) 2017-08-16
EP3080080A1 (en) 2016-10-19
US20220347157A1 (en) 2022-11-03
CN106029637A (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
US20220347157A1 (en) Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane
HUP0402104A2 (hu) 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenolt tartalmazó, késleltetett hatóanyag-leadású gyógyszer
CN104220068B (zh) 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物
NZ573382A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
TW201729812A (zh) 一種含有ｊａｋ激酶抑制劑或其可藥用鹽的醫藥組成物
KR20120003278A (ko) 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
JP2011507973A (ja) アムロジピンとバルサルタンとの医薬組成物
US11273156B2 (en) Stable cariprazine formulations for oral use
US20110274751A1 (en) Trimetazidine formulation with different release profiles
CN114867469A (zh) 包含氨基甲酸酯化合物的口服药物组合物及其制备方法
CN101926793A (zh) 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2236160A2 (en) Modified release dimebolin formulations
KR20090013736A (ko) 메트포르민 산 부가염을 포함하는 서방성 제제
US20250195440A1 (en) Pharmaceutical formulation comprising glucokinase activator and use thereof
US20120329831A1 (en) Pharmaceutical composition of donepezil
US20250134820A1 (en) Pharmaceutical compositions
EP2677868A2 (en) Pharmaceutical compositions of maraviroc and process for the preparation thereof
WO2010134097A2 (en) Stable pharmaceutical compositions of olanzapine and process for their preparation
WO2023080854A1 (en) Lurasidone hydrochloride compositions
WO2025133928A2 (en) Pharmaceutical matrices for prolonged drug release
CN119074728A (zh) 用于高血压治疗的多重释放组合物
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
WO2022079459A1 (en) A pharmaceutical composition comprising phthalazinone derivatives
HK40072206A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
WO2012172413A1 (en) Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application